Efficacy and safety of CD19 directed CAR T-cell therapy for central nervous system lymphoma.
Study #: LY22-02a
Study Status: Published
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Ramakrishnan Geethakumari P, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, Hamadani M, Herrera AF, Lee CJ.
Haematologica. 2024, Sep 05: (): . doi: 10.3324/haematol.2024.285613. Epub 2024, Sep 05. PMCID:.
PMID: 39234871
Abstract